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glucagon-like peptide 1 receptor (GLP-1r), and peripheral administration reduces food intake and
increases energy expenditure in rodents and humans. Substituting the native glutamine (Gln) at amino
acid position 3 of OXM for glutamate (Glu) has previously been shown to diminish GCGr activity without
affecting GLP-1r activity. The effects of Glu-3 OXM analogues have not been investigated in rats.
Methods: The effect of 2 Glu-3-substituted OXM-like analogues (eg, OXM14E3 and OXM15E3) on food
intake and body weight was investigated in male Wistar rats during 6 days of daily subcutaneous (SC)
administration. The effects of Glu-3 substitution on analogue binding and activity at the rat GCGr and rat
GLP-1 receptor were investigated in vitro using Chinese hamster ovary or Chinese hamster lung cells.
Results: We report the novel ﬁnding that 2 5-nmol/kg Glu-3 OXM-like analogues (OXM14E3 and
OXM15E3) signiﬁcantly increased rat body weight by up to 4% compared with the equivalent non-
Glu-3 analogues (OXM14 and OXM15), without affecting food intake. The effect of OXM15E3 on body
weight was dose–dependent. Glu-3 analogues, including Glu-3 OXM, decreased glucagon-mediated
cyclic adenosine monophosphate accumulation in Chinese hamster ovary cells expressing the rat GCGr,
suggesting they may be acting as antagonists.
Conclusions: The results indicate Glu-3 OXM-like analogues might not be suitable tools to investigate the
mechanism of OXM analogue action in a rat model because they signiﬁcantly increase body weight
independent of food intake. Glu-3 OXM analogues are partial agonists at the rat GCGr and may also act as
antagonists, possibly resulting in the observed increase in body weight.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
The gut-derived hormone oxyntomodulin (OXM) is a naturally
occurring dual agonist of both the glucagon receptor (GCGr) and
glucagons-like peptide 1 receptor (GLP-1r).1 Structurally OXM is
the 29 amino acids of glucagon with a C-terminal octapeptide tail.2
Administration of OXM to rodents and humans reduces food
intake and increases energy expenditure, generating signiﬁcant
weight loss and highlighting OXM as a potential pharmacologic
treatment for obesity.3,4 Due to the short in vivo half-life of native
OXM,5 it is necessary to produce long-lasting analogues for
clinical use.r Inc. This is an open access articl
D, Department of Investiga-
, London, W12 0NN, United
m).The dual agonist properties of OXM make investigating its
mechanism(s) of action difﬁcult. Using GCGr or GLP-1r antagonists
can interfere with the actions of endogenous glucagon and GLP-1,
hormones that play critical roles in glucose homeostasis, giving an
inaccurate picture of OXM actions. Alternatively, substituting
glutamine at position 3 of OXM with Glu has previously been
reported to diminish GCGr activity without affecting GLP-1r
activity,6,7 enabling investigation of mechanisms of action relating
to exogenous OXM administration.
These Glu-3 OXM analogues have been used in mice to
investigate the contribution of GCGr and GLP-1r activity to the
function of both native OXM7,8 and a derivatized analogue.6
Previous results indicate that OXM activity at the GLP-1r is
responsible for the reduction in food intake and activity at the
GCGr increases energy expenditure.6,7
Previous work in our lab designed OXM-like dual analogues of
the GCGr and GLP-1r based on the 29 amino acids of glucagon.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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increase GLP-1r activity, improve peptide stability, and extended
circulatory half-life, with a view to developing a potential treat-
ment for obesity. Several equivalent Glu-3 analogues were also
designed to investigate the contribution of GCGr and GLP-1r
activity to the effects of the OXM-like dual analogues. Our pilot
experiments suggested that Glu-3 OXM-like analogues increased
body weight in rats without affecting food intake; therefore,
further experiments were undertaken to clarify these ﬁndings.
The 2 Glu-3 analogues OXM14E3 and OXM15E3 were chosen for
investigation because they increased body weight in a pilot
experiment and had similar conservative amino acid substitutions
and pharmacokinetic proﬁles.
The results of our study suggest that Glu-3-substituted OXM
analogues may be partial agonists that can act as competitive
antagonists in vitro and increase body weight independent of food
intake in vivo. Therefore Glu-3 OXM analogues are not a suitable
tool to investigate the effects of OXM-like dual analogues in a
rat model.Methods
Compounds
All peptides (human glucagon, GLP-1, and OXM; analogues
OXM14 and OXM15 and their respective Glu-3 analogues
OXM14E3 and OXM15E3; and OXME3) were custom synthesized
by Insight Biotechnology Limited (Middlesex, United Kingdom)
and were 490% pure. The structure of analogues OXM14E3 and
OXM15E3 were based on the 29 amino acids of glucagon and,
other than the Glu-3 substitution, contained 6 single amino acid
substitutions between residues 12 through 29. Both analogues had
additional amino acids at residues 30 and 31 and OXM15E3 was
C-terminally amidated (Figure 1). These analogues were chosen for
investigation because they had similar pharmacokinetic proﬁles
but different afﬁnity and potency at the rat glucagon and GLP-1rs.
Animals
Male Wistar rats (Charles River, Margate, United Kingdom)
were maintained in individual cages under controlled temperature
(211C–231C) and light conditions (12:12 light-dark cycle, lights on
at 0700 hours) with ad libitum access to food (RM1 diet; SDS,
Witham, United Kingdom) and water unless otherwise stated. All
animal procedures were approved under the British Home Ofﬁce
Animals (Scientiﬁc Procedures) Act 1986 (Project Licence 70/7236).
In vivo food intake and body weight studies
Before study commencement, rats were randomized to treat-
ment groups with equal mean body weights. An injection of
peptide (maximum volume 50 mL, reconstituted in zinc chloride
to enhance peptide depot formation9,10) or vehicle (saline) wasGlucagon
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Figure 1. Schematic of the amino acid structures of the oxyntomodulin (OXM)-like dual
position 3.administered subcutaneously at 1600 hours daily and food and
body weight recorded.
Cell culture
All cell culture reagents were obtained from Invitrogen (Life
Technologies Ltd, Paisley, United Kingdom) unless otherwise
stated. Chinese hamster ovary-K1 cells overexpressing the rat
GCGr were routinely maintained in Dulbecco’s modiﬁed eagle
medium (DMEM) with 25 mM glucose and 1 mM sodium pyruvate
supplemented with 10% fetal bovine serum, 25 mM hydroxyethyl
piperazineethanesulfonic acid, 1% antibiotic (100 U/mL penicillin
and 100 mg/mL streptomycin), and 1  nonessential amino acids.
Chinese hamster lung cells overexpressing the rat GLP-1r were
maintained in the same DMEM but without additional hydrox-
yethyl piperazineethanesulfonic acid or nonessential amino acids.
In vitro cyclic adenosine monophosphate (cAMP) accumulation
Levels of cAMP accumulation was measured in Chinese hamster
ovary-K1 cells overexpressing the rat GCGr (cDNA from Origene,
Cambridge Bioscience, Cambridge, United Kingdom) or Chinese
hamster lung cells overexpressing the rat GLP-1r (a gift from
Bernard Thorens, University of Lausanne, Switzerland).
Cells were seeded in a 48-well plate (Nunc, VWR International
Inc, Chicago, Illinois) in their respective supplemented DMEM, at a
density of 37,500 cells/well (250 mL/well), then incubated for 24
hours. Cells were serum starved in DMEM þ1% antibiotic for
1 hour before 30 minutes’ incubation at room temperature with
peptide concentrations diluted in serum-free DMEM with 1 mM
IBMX (Sigma-Aldrich, Dorset, United Kingdom). Each peptide
concentration was applied in duplicate or triplicate per
experiment.
For rat GCGr antagonism studies, cells were incubated for 30
minutes with peptide concentrations diluted in serum-free DMEM
with 1 mM IBMX and 0.1 nM glucagon. Five wells of each
concentration and 12 wells of 0.1 nM glucagon alone were applied
per experiment.
Postincubation, medium was removed and cells lysed with 120
mL/well of 0.1 M hydrochloride þ 0.5% nonionic, octylphenol
ethoxylate surfactant. cAMP levels were measured using an
indirect ELISA according to the manufacturer’s instructions (ADI-
900-066, Enzo Life Sciences, United Kingdom), optical density was
read at 405 nm on a Biotek ELx808 (Wolf Laboratories, York,
United Kingdom). Data were plotted and in vivo efﬁcacy values
calculated.
In vitro receptor binding: Supplementary
Refer to O’Shea et al11 for detailed methods. Brieﬂy, membranes
were prepared from Chinese hamster ovary-K1 cells overexpress-
ing the rat GCGr or Chinese hamster lung cells overexpressing
the rat GLP-1r by osmotic lysis and differential centrifugation.e amino acid residue substitutions compared
 glucagon within this region
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polypropylene tubes with 100 pm (500 Bq) either iodine125 labeled
GLP-1 or iodine125 labeled glucagon in competition with unlabeled
peptide. Total speciﬁc binding was calculated as the difference in
counts between assays in the presence (nonspeciﬁc) and absence
(total) of up to 6000 nM peptides. Data were plotted and in vitro
afﬁnity values calculated.Statistical analysis
cAMP in vitro efﬁcacy and binding in vitro afﬁnity were
calculated using nonlinear regression with Prism version 5 soft-
ware (GraphPad Software Inc, San Diego, California). Differences in
cumulative food intake and body weight were analyzed using 1-
way ANOVA and post hoc tests with Dunnett or Bonferroni
correction (Prism version 5 software). In all cases P o 0.05 was
considered statistically signiﬁcant.Results
In vivo
Daily administration of 25 nmol/kg OXM14E3 to rats signiﬁ-
cantly increased body weight over 7 days (27.5 [2.2] g; P o 0.01)
compared with vehicle controls (11.4 [2.6] g) and OXM14 (9.2 [3.8]
g) (Figure 2B). Daily 25 nmol/kg OXM15E3 administration signiﬁ-
cantly increased body weight over 7 days (19 [3.3] g; P o 0.01)
compared with OXM15 (4.5 [2.7] g) (Figure 2B). Food intake was300
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Figure 2. (A) Food intake and (B) body weight change after 7 days of daily subcutaneous
(n ¼ 6–7). (C) Food intake and (D) body weight change after 7 days of daily SC adminis
mean (SEM). Statistical analysis was conducted using 1-way ANOVA and post hoc tests w
versus vehicle controls; ##P o 0.01 versus peptide with native glutamine at amino acidnot increased after administration of either OXM14E3 or OXM15E3
(Figure 2A).
Daily administration of 10 nmol/kg and 20 nmol/kg OXM15E3
resulted in a signiﬁcant increase in rat body weight over 7 days
(15.1 [1.9] g; P o 0.05 and 17.7 [1.5] g; P o 0.01, respectively)
compared with vehicle controls (7.9 [2.0] g) (Figure 2D), without
altering food intake (Figure 2C).
In vitro
At the rat GCGr the binding afﬁnity of the Glu-3 substituted
peptides OXM14E3 and OXM15E3 was 63-fold and 120-fold lower
compared with OXM14 and OXM15, respectively (Figure 3D).
Receptor binding afﬁnity for the Glu-3 analogues at the rat GLP-
1r was 2.7- to 4.4-fold greater than their Glu-3 counterparts
(Figure 3D).
Substituting Glu at position 3 decreased peptide efﬁcacy at the
rat GCGr. The efﬁcacy of OXM14E3, OXM15E3, and OXME3 was
200-, 25-, and 13-fold lower respectively compared with their Glu-
3 equivalents OXM14, OXM15, and OXM. Glu-3 substitution
increased rat GLP-1r efﬁcacy by 1.2- to 1.6-fold (Figure 3D).
Concentrations of 0.03 to 1 nM OXM14E3 (Figure 3A) and 0.03
to 0.3 nM OXM15E3 (Figure 3B) decreased the percentage of
glucagon-mediated cAMP production at the rat GCGr by a mean of
18.4% and 27.5%, respectively. Concentrations of 3 and 30 nM of
OXM14E3 and OXM15E3 increased cAMP levels compared with
glucagon stimulation alone (OXM14E3 30 nM: 155% increase,
OXM15E3 30nM: 214% increase) (Figure 3A-B). Except 30 nM, all
concentrations of OXME3 tested decreased glucagon-mediated
cAMP accumulation by a mean of 40.3% (Figure 3C). A 30-nM30
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Figure 3. In vitro cyclic adenosine monophosphate (cAMP) levels measured in Chinese hamster ovary cells overexpressing the rat glucagon receptor (rGCGr) following
incubation with various concentrations of (A) oxyntomodulin (OXM)14E3, (B) OXM15E3, or (C) OXME3 in the presence of 0.1 nM glucagon. Mean cAMP levels (SEM) are
shown as a percentage of the levels produced by glucagon stimulation alone (n ¼ 3). (D) Mean in vitro efﬁcacy (cAMP EC50) and afﬁnity (IC50) of OXM analogues and native
peptides at the rGCGr and rat glucagons-like peptide 1 receptor (rGLP-1r). cAMP EC50 values were calculated using Chinese hamster ovary cells overexpressing the rGCGr or
Chinese hamster lung cells overexpressing the rGLP-1r. IC50 values were calculated using membranes produced from the Chinese hamster ovary cells or Chinese hamster
lung cells (n ¼ 3).
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glucagon stimulation alone (Figure 3C).Discussion
Structurally, OXM is the 29 amino acids of glucagon with a
C-terminal octapeptide tail.2 The dual agonist activity of OXM at
the GCGr and GLP-1r makes it difﬁcult to investigate the mecha-
nisms involved in the weight-reducing effects of exogenous OXM
administration because receptor antagonists also block the actions
of endogenous glucagon and GLP-1. Previously it has been
reported that exchanging the position-3 glutamine of OXM or a
related analogue for Glu diminishes mouse GCGr activity without
affecting activity at the mouse GLP-1r.6,7 These GLP-1r selective
Glu-3 peptides offer an alternative method for investigating the
contribution of GCGr and GLP-1r activity to the metabolic effects of
OXM and related analogues. Several previous studies have used
Glu-3 analogues to explore the metabolic effects of OXM admin-
istration in mice, reporting that GCGr activity was necessary for,6–8
but the effect of Glu-3 peptide administration in rats has not been
investigated.
The present study reports the novel observation that substitut-
ing Glu at position 3 of 2 OXM-like dual analogues caused a
signiﬁcant increase in body weight in a rat model, without altering
food intake. In line with previous ﬁndings at the mouse receptor,6,7
in vitro activity at the rat GCGr was diminished by Glu-3 sub-
stitution. Interestingly, glucagon-mediated activation of the rat
GCGr in vitro was reduced by the lower concentrations of the Glu-
3 analogues tested, including Glu-3 of native OXM. This suggeststhat the Glu-3 OXM analogues may be partial agonists that can
also act as competitive antagonists in vitro, despite reduced rat
GCGr binding afﬁnity.
Glucagon administration increases energy expenditure12,13 and
in rodents this is postulated to be due to activation of brown
adipose tissue.14 Exogenous peripheral administration of native
OXM or long-acting analogues also increases energy expendi-
ture3,4,6 and several murine studies have suggested a GCGr-
mediated mechanism is responsible.6,7 Glu-3 OXM analogues
may antagonize the activity of endogenous glucagon, possibly
causing a reduction in energy expenditure and resulting in the
observed increase in rat body weight. However endogenous
glucagon has not been shown to play a tonic role in energy
expenditure or weight regulation. Investigation of the effects of
Glu-3 peptides on energy expenditure in rats is needed.
The increase in body weight following Glu-3 administration may
be a rat-speciﬁc phenomenon, as previous results with Glu-3 OXM-
like peptides were obtained in mice and did not show an increase.6,7
However the Glu-3 peptides used in these previous studies6,7 were
derivatized and administered at higher doses than in the present
study. A recently published study15 demonstrated that analogues of
glucose-dependent insulinotropic polypeptide (GIP) with a proline
substitution at amino acid position 3 (Pro-3) were full agonists at the
human GIP receptor and partial agonists that could acts as compet-
itive antagonists at the rat and mouse GIP receptor. It is possible this
may also be the case with Glu-3 OXM-like analogues. However, the
agonist or antagonist properties of Glu-3 analogues at the mouse and
human GCGrs have not been fully investigated. Additionally, differ-
ences in peptide and receptor homology between species may
contribute to the differential effects observed with GIP analogues
S.L. Price et al. / Current Therapeutic Research 77 (2015) 111–115 115with a proline substitution at amino acid position 3. Human GIP has
several different residues compared with rat and mouse GIP,15
whereas the amino acid sequences of glucagon and OXM are identical
in the 3 species. Therefore the relevance of the ﬁndings with Pro-3
GIP analogues to the present study is unclear.Conclusions
OXM-like analogues with a Glu-3 substitution signiﬁcantly
increase body weight in a rat model, independent of food intake.
Glu-3 analogues appear to be partial agonists at the rat GCGr and
can also act as competitive antagonists in vitro. Therefore Glu-3
OXM-like analogues are unsuitable tools to investigate the effects
of OXM analogue activity in a rat model.Acknowledgments
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